Komori
Treasury Shares4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Status of Share Buybacks and Completion of the Buyback

Under the resolution of 26 March 2026, the company repurchased 1,038,600 shares for approximately ¥3.0 billion between 7 August and 14 September. The repurchase ended partway through the resolution period because the maximum acquisition price had been reached.

Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
2999998289
¥
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Acquisition completedMarket purchases on the Tokyo Stock Exchange

Resolved 26 March 2026 / Acquisition period 27 March 2026 to 31 December 2026

69.2%
Cumulative utilization rate
Limit461,400 株 remaining
Number of Shares1,500,000 shares (maximum)
—
No Track Record Reported
Limit
Amount¥3 billion (maximum)

今回の取得が、そのまま決議後の累計です。

Number of Shares
Limit1,500,000 shares (maximum)
Cumulative total1,038,600 shares (as of 14 September 2026)
Current1,038,600 shares
Amount
Limit¥3 billion (maximum)
Cumulative total¥2,999,998,289 (as of 14 September 2026)
Current¥2,999,998,289
Percentage of total issued shares0.66%
Average acquisition price for this transaction (calculated)¥2,889 per shareCurrent acquisition price ÷ current number of shares acquired
Whether acquisition has been completed

Ended with the acquisition on 14 September 2026

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction1,038,600 shares
Total current acquisition price¥2,999,998,289
Acquisition date/acquisition period7 August 2026 to 14 September 2026
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Cumulative number of shares acquired1,038,600 shares (as of 14 September 2026)
Cumulative acquisition cost¥2,999,998,289 (as of 14 September 2026)
Resolution date26 March 2026
Maximum number of shares to be acquired1,500,000 shares (maximum)
Total acquisition price¥3 billion (maximum)
Acquisition period under the resolution27 March 2026 to 31 December 2026
Percentage of total issued shares0.66%
Whether acquisition has been completedEnded with the acquisition on 14 September 2026
Items this document does not state (1)
Average Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This was a share repurchase conducted under Article 459, Paragraph 1 of the Companies Act. With this repurchase, the company completed the acquisition of its own shares based on the resolution adopted at the Board of Directors meeting held on 26 March 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Buybacks and Completion of the Buyback | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori